Bivalent binding by intermediate affinity of nimotuzumab: A contribution to explain antibody clinical profile

Article

Abstract: Nimotuzumab is an EGFR-targeting antibody that has demonstrated encouraging clinical results in the

Palabras claves:

Affinity, Avidity, Cancer immunotherapy, eGFR, monoclonal antibodies, nimotuzumab, Tumor targeting

Autores:

Fernandez L.E., Garrido G., Gracia E., Iznaga N., Kerbel R.S., Pérez R., Rabasa A., Tania Crombet, Tikhomirov I.A., Yang E.

Fuentes:

scopus